Nanosolvated microtubule-modulating chemotherapeutics

Abstract

About 10% of the drugs in the preclinical stage are poorly soluble, 40% of the drugs in the pipeline have poor solubility, and even 60% of drugs coming directly from synthesis have aqueous solubility below 0.1 mg/ml. Out of the research around, 40% of lipophilic drug candidates fail to reach the market despite having potential pharmacodynamic activities. Microtubule-modulating chemotherapeutics is an important class of cancer chemotherapy. Most chemotherapeutics that belong to this category are plant-derived active constituents, such as vincristine, vinblastine, colchicine, docetaxel, paclitaxel, and noscapinoids. The pKa of a drug considerably affects its solubility in physiological fluids and consequently bioavailability. It usually ranges from 5 to 12 for microtubule-modulating drugs. Hence, the solubility of these drugs in physiological fluids is considerably affected by a change in pH. However, because of unpredictable parameters involved in poor solubility and the low oral bioavailability of these chemotherapeutics during the early phases of drug development, they often have an unusual pharmacokinetic profile. This makes the development process of novel chemotherapeutics slow, inefficient, patient-unfriendly, and very costly, emphasizing a need for more rational approaches on the basis of preclinical concepts. Nanosolvation is a process of increasing the polarity of a hydrophobic molecule either by solvation or cavitization in a hydrophilic macrocycle. The present review therefore focuses on the techniques applied in nanosolvation of microtubule-modulating chemotherapeutics to enhance solubility and bioavailability. The methodologies described will be highly beneficial for anticancer researchers to follow a trend of rational drug development.

Decoding the silent walk of COVID-19: Halting its spread using old bullets

“…NOS, ( Fig. 3 ) an opium alkaloid classically used as antitussive agent has been repositioned for its anti-tumor effect as it strongly binds to tubulin, arrests the cells in metaphase, induces apoptosis in the dividing human cells and has the advantage of large therapeutic window [ [116] , [117] , [118] , [119] , [120] , [121] , [122] ]. The antitussive effect of NOS is documented through suppression of bradykinin production or inhibition of its function through inhibition of B2 receptor thus preventing bronchoconstriction, mucous production and histamine release [ [123] , [124] ].…”

Study of the Chemical Composition and Antimicrobial Activity of Extracts From Tagetes Patula L.

“…Для приготовления экстракта № 2 (водно-спиртового) и экстракта № 4 (водного) 10 г измельченного растительного сырья помещали в емкость из темного стекла объемом 200 мл, добавляли 150 мл 70%-ного этанола и оставляли при периодическом перемешивании на 3 суток. Извлечение фильтровали через несколько слоев марли, отжимая частицы сырья [9]. Исследование содержания в экстрактах основных групп биологически активных веществ проводили с использованием качественных реакций: реакции для определения флавоноидов (реакция с хлоридом железа (III), реакции с аммиаком, борно-лимонная реакция), для определения гликозидов (реакция Келлер-Килиани); реакции осаждения для определения алкалоидов (реакция Вагнера-Бушарда, реакция Марки) [9,10].…”

Recent Advances in Macrocyclic Hsp90 Inhibitors

“…10 Although membrane permeability is enhanced by cyclisation, macrocycles are often plagued by poor solubility issues due to hydrophobic residues that are typically incorporated within the structural backbone. 11 Scaling up syntheses of macrocycles from preclinical studies into early clinical trials is typically challenging if there are no repetitive elements or biosynthetic pathways to be utilised. 5 The advantages and disadvantages of the macrocyclic structure are prominently illustrated in Hsp90 research, where several macrocyclic Hsp90 inhibitors have been removed from further clinical study when the molecular promise was outweighed by the side-effects.…”